Management of multi-drug resistant Helicobacter pylori infection by supplementary, complementary and alternative medicine; a review
Gastroenterology and Hepatology from Bed to Bench,
AbstractHelicobacter pylori is recognized as the most common bacterial pathogens colonizing the gastric epithelium of nearly half of the world’s population. This bacterium is the main etiological cause of gastroduodenal ulcers, and more importantly as the substantial risk factor for development of gastric cancer. The emergence and rapid increase in the prevalence of multi-drug resistant phenotypes have posed major pitfalls in effectiveness of various treatment regimens and eradication strategies against H. pylori infections. Several natural products and supplementary food components have been reported to have established anti-H. pylori activity. Herein, we review the application and efficacy of some specific natural products and foodstuffs such as milk, bee products (honey and propolis), fish oil, vitamins C and E, and also a nickel free-diet used as anti-H. pylori alternative treatment regimens
- Helicobacter pylori
- Drug resistance
- Dietary supplementation
- Eradication therapy
How to Cite
Ahn HJ, Lee DS. Helicobacter pylori in gastric carcinogenesis. World J Gastrointest Oncol 2015;7:455-65.
Bauer B, Meyer TF. The human gastric pathogen Helicobacter pylori and its association with gastric cancer and ulcer disease. Ulcers 2011;2011:1-23
Kao C-Y, Chen J-W, Huang Y-T, Sheu S-M, Sheu B-S, Wu J-J. Genome sequence and annotation of Helicobacter pylori strain Hp238, isolated from a Taiwanese patient with mucosa-associated lymphoid tissue lymphoma. Genome Announc 2015;3:e00006-15.
Wroblewski LE, Peek RM, Wilson KT. Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev 2010;23:713-39.
Kao C-Y, Sheu B-S, Wu J-J. Helicobacter pylori infection: An overview of bacterial virulence factors and pathogenesis. Biomed J 2016;39:14-23.
Yadegar A, Alebouyeh M, Lawson AJ, Mirzaei T, Nazemalhosseini Mojarad E, Zali MR. Differentiation of non-pylori Helicobacter species based on PCR-restriction fragment length polymorphism of the 23S rRNA gene. World J Microbiol Biotechnol 2014;30:1909-17.
Yadegar A, Alebouyeh M, Zali MR. Analysis of the intactness of Helicobacter pylori cag pathogenicity island in Iranian strains by a new PCR-based strategy and its relationship with virulence genotypes and EPIYA motifs. Infect Genet Evol 2015;35:19-26.
Cover TL. Helicobacter pylori diversity and gastric cancer risk. MBio 2016;7:e01869-15.
Gunaletchumy SP, Seevasant I, Tan MH, Croft LJ, Mitchell HM, Goh KL, et al. Helicobacter pylori genetic diversity and gastro-duodenal diseases in Malaysia. Sci Rep 2014;4:7431.
Farzi N, Malekian T, Alebouyeh M, Vaziri F, Zali MR. Genotype diversity and quasispecies development of Helicobacter pylori in a single host. Jpn J Infect Dis 2015;68:176-80.
Sugimoto M, Yamaoka Y. Virulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy. Arch Immunol Ther Exp (Warsz) 2009;57:45-56.
Boehnke KF, Valdivieso M, Bussalleu A, Sexton R, Thompson KC, Osorio S, et al. Antibiotic resistance among Helicobacter pylori clinical isolates in Lima, Peru. Infect Drug Resist 2017;10:85-90.
Megraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004;53:1374-84.
Vianna JS, Ramis IB, Ramos DF, VON GROLL A, Silva PEAd. Drug resistance in Helicobacter pylori. Arq Gastroenterol 2016;53:215-23.
Thung I, Aramin H, Vavinskaya V, Gupta S, Park J, Crowe S, et al. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther 2016;43:514-33.
Shokrzadeh L, Alebouyeh M, Mirzaei T, Farzi N, Zali MR. Prevalence of multiple drug-resistant Helicobacter pylori strains among patients with different gastric disorders in Iran. Microb Drug Resist 2015;21:105-10.
Alebouyeh M, Yadegar A, Farzi N, Miri M, Zojaji H, Gharibi S, et al. Impacts of H. pylori mixed-infection and heteroresistance on clinical outcomes. Gastroenterol Hepatol Bed Bench 2015;8(Suppl 1):S1-5.
Lahov E, Regelson W. Antibacterial and immunostimulating casein-derived substances from milk: casecidin, isracidin peptides. Food Chem Toxicol 1996;34:131-45.
Chan GM. Effects of powdered human milk fortifiers on the antibacterial actions of human milk. J Perinatol 2003;23:620-3.
Farnaud S, Evans RW. Lactoferrin--a multifunctional protein with antimicrobial properties. Mol Immunol 2003;40:395-405.
Jenssen H, Hancock RE. Antimicrobial properties of lactoferrin. Biochimie 2009;91:19-29.
Fahey JW, Stephenson KK, Wallace AJ. Dietary amelioration of Helicobacter infection. Nutr Res 2015;35:461-73.
Roşeanu A, Damian M, Evans RW. Mechanisms of the antibacterial activity of lactoferrin and lactoferrin-derived peptides. Rom J Biochem 2010;47:203-9.
Hołubiuk Ł, Imiela J. Diet and Helicobacter pylori infection. Gastroenterol Rev 2016;11:150-154.
Di Mario F, Aragona G, Dal Bò N, Ingegnoli A, Cavestro GM, Moussa AM, et al. Use of lactoferrin for Helicobacter pylori eradication. J Clin Gastroenterol 2003;36:396-8.
Dial E, Romero J, Headon D, Lichtenberger L. Recombinant human lactoferrin is effective in the treatment of Helicobacter felis‐infected mice. J Pharm Pharmacol 2000;52:1541-6.
Okuda M, Nakazawa T, Yamauchi K, Miyashiro E, Koizumi R, Booka M, et al. Bovine lactoferrin is effective to suppress Helicobacter pylori colonization in the human stomach: a randomized, double-blind, placebo-controlled study. J Infect Chemother 2005;11:265-9.
Wang X, Hirmo S, Willen R, Wadström T. Inhibition of Helicobacter pylori infection by bovine milk glycoconjugates in a BALB/cA mouse model. J Med Microbiol 2001;50:430-5.
Akedo I, Tatsuta M, Narahara H, Iishi H, Uedo N, Yano H, et al. Prevention by bovine milk against Helicobacter pylori-associated atrophic gastritis through its adherence inhibition. Hepatogastroenterology 2003;51:277-81.
Okuda M, Miyashiro E, Koike M, Okuda S, Minami K, Yoshikawa N. Breast‐feeding prevents Helicobacter pylori infection in early childhood. Pediatr Int 2001;43:714-5.
Sachdeva A, Rawat S, Nagpal J. Efficacy of fermented milk and whey proteins in Helicobacter pylori eradication: a review. World J Gastroenterol 2014;20:724-37.
Lusby P, Coombes A, Wilkinson J. Honey: a potent agent for wound healing? J Wound Ostomy Continence Nurs 2002;29:295-300.
Hegazi AG, Al Guthami FM, Al Gethami AF, Allah FMA, Saleh AA, Fouad EA. Potential antibacterial activity of some Saudi Arabia honey. Vet World 2017;10:233-237.
Wasihun AG, Kasa BG. Evaluation of antibacterial activity of honey against multidrug resistant bacteria in Ayder Referral and Teaching Hospital, Northern Ethiopia. SpringerPlus 2016;5:842.
Abdel-Latif MM, Abouzied MM. Molecular mechanisms of natural honey against H. pylori infection via suppression of NF-κB and AP-1 activation in gastric epithelial cells. Arch Med Res 2016;47:340-8.
Boyanova L, Ilieva J, Gergova G, Vladimirov B, Nikolov R, Mitov I. Honey and green/black tea consumption may reduce the risk of Helicobacter pylori infection. Diagn Microbiol Infect Dis 2015;82:85-6.
Manyi-Loh CE, Clarke AM, Green E, Ndip RN. Inhibitory and bactericidal activity of selected South African honeys and their solvent extracts against clinical isolates of Helicobacter pylori. Pak J Pharm Sci 2013;26:897-906.
Matongo F, Nwodo UU. In vitro assessment of Helicobacter pylori ureases inhibition by honey fractions. Arch Med Res 2014;45:540-6.
Boonsai P, Phuwapraisirisan P, Chanchao C. Antibacterial activity of a cardanol from Thai Apis mellifera propolis. Int J Med Sci 2014;11:327-36.
Cui K, Lu W, Zhu L, Shen X, Huang J. Caffeic acid phenethyl ester (CAPE), an active component of propolis, inhibits Helicobacter pylori peptide deformylase activity. Biochem Biophys Res Commun 2013;435:289-94.
Baltas N, Karaoglu SA, Tarakci C, Kolayli S. Effect of propolis in gastric disorders: inhibition studies on the growth of Helicobacter pylori and production of its urease. J Enzyme Inhib Med Chem 2016;31(sup2):46-50.
Villanueva M, Gonzalez M, Fernandez H, Wilson M, Manquian N, Otth C, et al. In vitro antibacterial activity of Chilean propolis against Helicobacter pylori. Rev Chilena Infectol 2015;32:530-5.
Bergonzelli G, Donnicola D, Porta N, Corthesy-Theulaz I. Essential oils as components of a diet-based approach to management of Helicobacter infection. Antimicrob Agents Chemother 2003;47:3240-6.
Chun S-S, Vattem DA, Lin Y-T, Shetty K. Phenolic antioxidants from clonal oregano (Origanum vulgare) with antimicrobial activity against Helicobacter pylori. Process Biochem 2005;40:809-16.
Hawthorne A, Daneshmend T, Hawkey C, Belluzzi A, Everitt S, Holmes G, et al. Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial. Gut 1992;33:922-8.
Kemen M, Senkal M, Homann H-H, Mumme A, Dauphin A-K, Baier J, et al. Early postoperative enteral nutrition with arginine-omega-3 fatty acids and ribonucleic acid-supplemented diet versus placebo in cancer patients: An immunologic evaluation of Impact Registered Trademark. Crit Care Med 1995;23:652-9.
Nordøy A. Is there a rational use for n-3 fatty acids (fish oils) in clinical medicine? Drugs 1991;42:331-42.
Senkal M, Kemen M, Homann H, Eickhoff U, Baier J, Zumtobel V. Modulation of postoperative immune response by enteral nutrition with a diet enriched with arginine, RNA, and omega-3 fatty acids in patients with upper gastrointestinal cancer. Eur J Surg 1995;161:115-22.
Thompson L, Cockayne A, Spiller R. Inhibitory effect of polyunsaturated fatty acids on the growth of Helicobacter pylori: a possible explanation of the effect of diet on peptic ulceration. Gut 1994;35:1557-61.
Riber C, Wøjdemann M, Bisgaard T, Ingels H, Rehfeld J, Olsen O. Fish oil reduces gastric acid secretion. Scand J Gastroenterol 1999;34:845-8.
Zurier R. Fatty acids, inflammation and immune responses. Prostaglandins Leukot Essent Fatty Acids 1993;48:57-62.
Drago L, Mombelli B, Ciardo G, Vecchi ED, Gismondo M. Effects of three different fish Oil7 formulations on Helicobacter pylori growth and viability: in vitro study. J Chemother 1999;11:207-10.
Nualart FJ, Rivas CI, Montecinos VP, Godoy AS, Guaiquil VH, Golde DW, et al. Recycling of vitamin C by a bystander effect. J Biol Chem 2003;278:10128-33.
Tsao C. An overview of ascorbic acid chemistry and biochemistry. In: Packer L, FuchsJ, eds. Vitamin C in Health and Disease. New York: Marcel Dekker, 1997;p.25-58.
Deutsch JC. Spontaneous hydrolysis and dehydration of dehydroascorbic acid in aqueous solution. Anal Biochem 1998;260:223-9.
Sezikli M, Çetinkaya ZA, Sezikli H, Güzelbulut F, Tiftikçi A, Tüzün İnce A, et al. Oxidative stress in Helicobacter pylori infection: does supplementation with vitamins C and E increase the eradication rate? Helicobacter 2009;14:280-5.
Sezikli M, Cetinkaya Z, Güzelbulut F, Yeşil A, Coşgun S, Kurdaş O. Supplementing Vitamins C and E to standard triple therapy for the eradication of Helicobacter pylori. J Clin Pharm and Ther 2012;37:282-5.
Sjunnesson H, Sturegård E, Willén R, Wadström T. High intake of selenium, beta-carotene, and vitamins A, C, and E reduces growth of Helicobacter pylori in the guinea Pig. Comp Med 2001;51:418-23.
Sun YQ, Girgensone I, Leanderson P, Petersson F, Borch K. Effects of antioxidant vitamin supplements on Helicobacter pylori‐induced gastritis in Mongolian gerbils. Helicobacter 2005;10:33-42.
Zhang Z, Patchett S, Perrett D, Katelaris P, Domizio P, Farthing M. The relation between gastric vitamin C concentrations, mucosal histology, and CagA seropositivity in the human stomach. Gut 1998;43:322-6.
Jarosz M, Dzieniszewski J, Dabrowska-Ufniarz E, Wartanowicz M, Ziemlanski S, Reed P. Effects of high dose vitamin C treatment on Helicobacter pylori infection and total vitamin C concentration in gastric juice. Eur J Cancer Prev 1998;7(6):449-54.
Demirci H, Uygun İlikhan S, Öztürk K, Üstündağ Y, Kurt Ö, Bilici M, et al. Influence of vitamin C and E supplementation on the eradication rates of triple and quadruple eradication regimens for Helicobacter pylori infection. Turk J Gastroenterol 2015;26:456-60.
Zojaji H, Talaie R, Mirsattari D, Haghazali M, Molaei M, Mohsenian N, et al. The efficacy of Helicobacter pylori eradication regimen with and without vitamin C supplementation. Dig Liver Dis 2009;41:644-7.
Campanale M, Nucera E, Ojetti V, Cesario V, Di Rienzo T, D’Angelo G, et al. Nickel free-diet enhances the Helicobacter pylori eradication rate: a pilot study. Dig Dis Sci 2014;59:1851-5.
Buckley M, Scanlon C, McGurgan P, O'morain C. A validated dyspepsia symptom score. Ital J Gastroenterol Hepatol 1997;29:495-500.
Minelli M, Schiavino D, Musca F, Bruno M, Falagiani P, Mistrello G, et al. Oral hyposensitization to nickel induces clinical improvement and a decrease in TH1 and TH2 cytokines in patients with systemic nickel allergy syndrome. Int J Immunopathol Pharmacol 2010;23:193-201.
Fulgione A, Nocerino N, Iannaccone M, Roperto S, Capuano F, Roveri N, et al. Lactoferrin adsorbed onto biomimetic hydroxyapatite nanocrystals controlling-in vivo-the Helicobacter pylori infection. PloS one 2016;11:e0158646.
- Abstract Viewed: 2540 times
- PDF Downloaded: 173 times